Lindahl has advised ISR Immune System Regulation Holding AB (publ) when entering into agreement with Singapore Resources Development PTE. Ltd. regarding investment in subsidiary for development of inhalable covid-19 vaccine.
ISR Immune System Regulation Holding AB (publ) is a drug developing company within the area of immunotherapy. The company performs research and develops novel drugs for treatments of viral infections and cancer. In addition, the company develops inhalable covid-19 vaccine.
Singapore Resources Development PTE. Ltd. is a company specialized in developing business relations and investments in countries such as Indonesia, China and India. By gathering investors to specific business projects the company creates a business platform in the countries best suitable for respective project.
ISR is now heading towards a clinical trials phase of its vaccine program and to establish favorable conditions for further collaborations ISR sets up a specific vaccine company. Singapore Resources Development PTE. Ltd. invests in tranches and will invest, following the fulfillment of certain conditions, a total of EUR 6,850,000 for a total ownership of about 29 per cent in the subsidiary.
Lindahl’s team mainly consisted of Moritz Veller, Monica Lagercrantz, Johan Åberg, Mikael Nagy and Lisa Liljekvist.
